R&D Systems, Inc.

On February 10, 2014, Techne Corporation, R&D Systems parent company, announced that it will be operating under the new trade name, Bio-Techne. The use of Bio-Techne will bring the company’s R&D Systems, BiosPacific, Tocris Biosciences, Boston Biochem and Bionostics products under one common brand name. For more information on Bio-Techne please visit bio-techne.com.

R&D Systems, a Minnesota-based biological products company, started by producing hematology controls and calibrators for use in hospitals and clinics. In 1977, we introduced our first product, a platelet-rich-plasma control, and in 1981, we became the second manufacturer in the world to release a whole blood control with platelets. Over the years, R&D Systems Hematology has continued to develop a variety of hematology controls. These products continue to be available through our Clinical Controls Division.

In 1985, we released our first research reagent, TGF-beta 1, becoming the first company in the world to produce this cytokine commercially. TGF-beta 1 acts as an extracellular signaling molecule that is produced by many cell types. It is involved in such processes as immune function, cell proliferation, and cell differentiation. Following the launch of this product, we purified several other cytokines from natural sources and released them to the research market. Of great interest to biomedical researchers, cytokines are specialized proteins mediating communication between cells. They have many biological activities including regulating developmental processes and orchestrating the immune response. In addition, unregulated cytokine activity has been linked to many diseases including cancer, cardiovascular disease, and inflammatory disorders.

Encouraged by success in the cytokine market, we formed the Growth Factor (now known as Biotechnology) Division in 1985 with the goal of producing and marketing a wide range of human cytokines through genetic engineering. Recombinant DNA technology offers several advantages over extraction of these proteins from natural sources, including lower production cost and potentially unlimited supply. In 1989, the Biotechnology Division began developing monoclonal and polyclonal antibodies to cytokines, and in 1990 we developed our first enzyme-linked immunosorbent assay (ELISA) kit.

Currently, R&D Systems, Tocris Bioscience, and Boston Biochem will serve as the flagship brands in Bio-Techne's life science portfolio. In the coming months a new corporate identity, including new packaging, new literature, new trade show booth, as well as a new unified website will be introduced to customers.

R&D Systems, Inc. 614 McKinley Place NE Minneapolis, MN 55413 Toll Free USA, Canada
Jun 11, 2018
Scholarship - General
DEADLINE:  July 20, 2018 How to Apply Download and complete the scholarship application form. Submit a transcript of all college/post-secondary coursework (if high school student submit high school transcript). Submit a written statement addressing the following topics: Submit a 140 character statement/tweet on what you believe is the biggest hurdle for people working in your specific field of interest and why Write a personal statement of 500 words or less on how you plan to use your degree to further advance science in your field of interest. Eligibility Applicants must have a major declared in a science related field. Open worldwide. Enrolled or accepted for enrollment (baccalaureate, graduate, associate degree, or diploma) with a declared major in a science related field. Selection and notification process Deadline for this application is July 20, 2018 at 11:59 p.m. MST. Finalist will be notified by August 3, 2018. Submission guidelines Please submit your application online or email it to scholarship@novusbio.com by July 20, 2018 to be considered for the Fall 2018 R&D Systems Scholarship.